المؤلفون: Dimachkie, Mazen M., Barohn, Richard J., Byrne, Barry J., Goker-Alpan, Özlem, Kishnani, Priya Sunil, Ladha, Shafeeq S., Laforêt, Pascal, Mengel, Eugen, Peña, Loren D.M., Sacconi, Sabrina, Straub, V., Trivedi, Jaya R., van Damme, Philip, van der Ploeg, Ans Tjitske, Vissing, John, Young, Peter, Haack, Kristina An, Foster, Meredith C., Gilbert, Jane M., Miossec, Patrick, Vitse, Olivier, Zhou, Tianyue, Schoser, Benedikt Gustav Heinrich

المساهمون: Handicap neuromusculaire : Physiopathologie, Biothérapie et Pharmacologies appliquées (END-ICAP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Raymond Poincaré (Garches) GHU AP-HP Université Paris-Saclay, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Jean Verdier AP-HP, U.S. Food and Drug Administration, FDA, Genentech, GlaxoSmithKline, GSK, Sanofi, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Sanofi Genzyme, Sarepta Therapeutics, SRPT, Spark Therapeutics, Roivant Sciences, M.M. Dimachkie serves or recently served as a consultant—Amazentis, argenx, Catalyst, Cello, Covance/Labcorp, CSL-Behring, EcoR1, Janssen, Kezar, Momenta, NuFactor, Octapharma, RaPharma/UCB, Roivant Sciences Inc., RMS Medical, Sanofi Genzyme, Shire Takeda, Scholar Rock, Spark Therapeutics, Third Rock, and UCB Biopharma—and received research grants or contracts or educational grants from Alexion, Alnylam Pharmaceuticals, Amicus, BioMarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics, UCB Biopharma/RaPharma, Viromed/Helixmith, and TMA. R.J. Barohn: consulting fees—NuFactor and Momenta Pharmaceutical, contracted research—FDA Office of Orphan Products Development, NIH, Orphazyme, PCORI, PTC Therapeutics, Ra Pharma, and Sanofi Genzyme. B. Byrne: advisory board—Sanofi Genzyme. O. Goker-Alpan: advisory board—Amicus, BioMarin, Sanofi Genzyme, and Takeda, consulting fees—Amicus, BioMarin, Sanofi Genzyme, Shire HGT, and Takeda, contracted research—Amicus, Freeline, Genentech, Protalix, Sangamo, Sanofi Genzyme, and Takeda, and speaker's bureau—Sanofi Genzyme and Takeda. P.S. Kishnani: advisory board—Pompe and Gaucher Disease Registry Advisory Board for Sanofi Genzyme, Amicus Therapeutics, and Baebies, consulting fees—Sanofi Genzyme, Amicus Therapeutics, Maze Therapeutics, JCR Pharma, and Asklepios BioPharmaceutical, Inc. (AskBio), contracted research—Sanofi Genzyme, Valerion Therapeutics, and Amicus Therapeutics, honoraria—Sanofi Genzyme, Maze Therapeutics, Asklepios Biopharmaceutical, Inc. (AskBio), and Amicus Therapeutics, ownership interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds)—Asklepios Biopharmaceutical, Inc. (AskBio) and Maze Therapeutics, and travel expenses—Sanofi Genzyme and Amicus Therapeutics. S. Ladha: advisory board—Sanofi Genzyme, consulting fees—Sanofi Genzyme, contracted research—Sanofi Genzyme, and speaker's bureau—Sanofi Genzyme. P. Laforêt: advisory board—Sanofi Genzyme and Spark Therapeutics, honoraria—BioMarin, Sanofi Genzyme, and Spark Therapeutics, and travel expenses—Sanofi Genzyme, Amicus Therapeutics, and Spark Therapeutics. K.E. Mengel: advisory board—Actelion, Sanofi Genzyme, Takeda Shire, and Amicus, consulting fees—Orphazyme and Prevail, and contracted research—Orphazyme, Sanofi Genzyme, Shire, Idorsia, and Takeda Shire. L.D.M Peña: advisory board—AveXis Inc, consulting fees—AveXis Inc., contracted research—Shire Takeda, Chiesi, and ModernaTx, Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents—Castle IRB, speaker's bureau—France Foundation, and travel expenses—France Foundation. S. Sacconi: advisory board—Alnylam Pharmaceuticals, Biogen, BioMarin, and Sanofi Genzyme, consulting fees—Alnylam Pharmaceuticals, Biogen, BioMarin, Sanofi Genzyme, AEC partners, BresMed, Sanofi-Aventis France, and argenx BV, contracted research—AFM, and travel expenses—Biogen, BioMarin, and Sanofi Genzyme. V. Straub: consulting fees—AveXis Inc, Exonics Therapeutics, Roche, Sanofi Genzyme, and Sarepta Therapeutics, contracted research—Sanofi Genzyme and Ultragenyx, and honoraria—Sanofi Genzyme. J. Trivedi: contracted research—Sanofi Genzyme. P. Van Damme: advisory board—Biogen, Alexion Pharmaceuticals, Ferrer, QurAlis, and argenx. A.T. van der Ploeg: advisory board—Amicus, BioMarin, Sanofi Genzyme, and Spark Therapeutics, consulting fees—Amicus, BioMarin, Sanofi Genzyme, and Spark Therapeutics, and contracted research—Amicus, BioMarin, Sanofi Genzyme, and Spark Therapeutics. J. Vissing: advisory board—argenx, Roche, Viela Bio, Biogen, Amicus Therapeutics, PTC Therapeutics, Sanofi Genzyme, Ultragenyx Pharmaceutical, Fulcrum Therapeutics, ML Bio Solutions, Sarepta Therapeutics, Novartis Pharma AG, Stealth Biotherapeutics, Zogenix, Regeneron, and Lupin Limited, consulting fees—argenx, Roche, Viela Bio, Biogen, Amicus Therapeutics, PTC Therapeutics, Sanofi Genzyme, Ultragenyx Pharmaceutical, Fulcrum Therapeutics, ML Bio Solutions, Sarepta Therapeutics, Novartis Pharma AG, Stealth Biotherapeutics, Zogenix, Regeneron, and Lupin Limited, contracted research—argenx, Amicus Therapeutics, PTC Therapeutics, Sanofi Genzyme, Novartis Pharma AG, Stealth Biotherapeutics, UCB Pharma, and Genethon, employee/salary—Edgewise, and travel expenses—argenx, Roche, Viela Bio, Biogen, Sanofi Genzyme, ML Bio Solutions, and Sarepta Therapeutics. P. Young: advisory board—Biogen, BioMarin, Medice, Sanofi Genzyme, and Vanda, honoraria—Biogen, BioMarin, Löwenstein Medical, Medice, Sanofi Genzyme, UCB, and Vanda, and speaker's bureau—Biogen, BioMarin, Löwenstein Medical, Medice, Sanofi Genzyme, UCB, and Vanda. K. An Haack: employee/salary—Sanofi Genzyme (spouse: employee/salary—Sanofi Genzyme). M. Foster: employee/salary—Sanofi Genzyme, ownership interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds)—Sanofi Genzyme. J.M. Gilbert: employee/salary—Elevate Medical Affairs (contracted by Sanofi Genzyme for publication support services). P. Miossec: employee/salary—Sanofi Genzyme, ownership interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds)—Sanofi Genzyme. O. Vitse: employee/salary—Sanofi Genzyme, ownership interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds)—Sanofi Genzyme. T. Zhou: employee/salary—Sanofi Genzyme, ownership interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds)—Sanofi Genzyme. B. Schoser: advisory board—Amicus, Alexion, Audentes, Dyne, Lupin, Sanofi Genzyme, and UCB, contracted research—Amicus and Sanofi Genzyme, honoraria—Kedrion, and travel expenses—Sanofi Genzyme. Go to Neurology.org/N for full disclosures., The Article Processing Charge was funded by Sanofi.

المصدر: ISSN: 0028-3878.

مصطلحات موضوعية: [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35618441; hal-03775812; https://hal.science/hal-03775812Test; https://hal.science/hal-03775812/documentTest; https://hal.science/hal-03775812/file/e536.full.pdfTest; PUBMED: 35618441

الإتاحة: https://doi.org/10.1212/WNL.0000000000200746Test
https://hal.science/hal-03775812Test
https://hal.science/hal-03775812/documentTest
https://hal.science/hal-03775812/file/e536.full.pdfTest

المؤلفون: Honaker, Julie A., Gilbert, Jane M., Shepard, Neil T., Blum, Daniel J., Staab, Jeffrey P.

المصدر: American Journal of Otolaryngology ; volume 34, issue 5, page 592-595 ; ISSN 0196-0709

مصطلحات موضوعية: Otorhinolaryngology

الإتاحة: https://doi.org/10.1016/j.amjoto.2013.02.002Test
https://api.elsevier.com/content/article/PII:S019607091300046X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S019607091300046X?httpAccept=text/plainTest

المؤلفون: Honaker, Julie A., Gilbert, Jane M., Staab, Jeffrey P.

المصدر: Special Education and Communication Disorders Faculty Publications

مصطلحات موضوعية: dizziness, chronic subjective dizziness, conversion disorder, Special Education and Teaching, Speech Pathology and Audiology

وصف الملف: application/pdf

العلاقة: https://digitalcommons.unl.edu/specedfacpub/21Test; https://digitalcommons.unl.edu/context/specedfacpub/article/1021/viewcontent/csd_vs_conversion.pdfTest

الإتاحة: https://digitalcommons.unl.edu/specedfacpub/21Test
https://digitalcommons.unl.edu/context/specedfacpub/article/1021/viewcontent/csd_vs_conversion.pdfTest

المؤلفون: Honaker, Julie A.¹, Gilbert, Jane M.², Staab, Jeffrey P.²

المصدر: American Journal of Audiology. Jun2010, Vol. 19 Issue 1, p3-8. 6p. 1 Chart.

مصطلحات موضوعية: *AUDIOLOGISTS, *CHRONIC diseases, *DIZZINESS, *AUDIOLOGY, *AUDIOLOGIST & patient, *PATIENTS